Cav2.2-mediated NMDA Receptor Signaling in Short-Term Memory

Ying Zhou,Kimie Niimi,Weidong Li,Eiki Takahashi
DOI: https://doi.org/10.15761/imm.1000126
2015-01-01
Integrative Molecular Medicine
Abstract:It has been reported that Cav2.1-mediated N-methyl-D-aspartate (NMDA) receptor signaling is critical pathway in hippocampus and nucleus accumbens for spatial short-term memory. Neuronal voltage-dependent Cav2.1 and Cav2.2 have predominantly expressions at presynaptic neuronal terminals and mediate glutamate release in the central nervous systems. Recently, although Cav2.2 in the hippocampus and nucleus accumbens is also critical for spatial cognition, it remains unknown that functional Cav2.2-mediated NMDA receptor signaling in cognitive performance at the system level. This study examined whether Cav2.2-mediated NMDA receptor signaling mediates spatial short-term memory using the Y-maze test via a combined subthreshold doses of pharmacological approach. In previous our studies, Mice received systemic injection of NMDA receptor blocker (+/–)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP, 5mg/kg), mice received intrahippocampal injection of Cav2.2 blocker (ω-conotoxin GVIA, 1pg/side), or mice received intra-accumbens injection of Cav2.2 blocker (ω-conotoxin GVIA, 1pg/ side) were ineffective for the spatial short-term memory. However, a combination of subthreshold doses of 5mg/kg CPP systemic injection and 1pg/side ω-conotoxin GVIA intra-hippocampal injection triggered a spatial short-term memory deficit. Furthermore, a combination of subthreshold doses of 5mg/kg CPP systemic injection and 1pg/side ω-conotoxin GVIA intra-accumbens injection also showed impaired spontaneous alternation patterns. These results indicate that Cav2.2mediated NMDA receptor signaling is critical in the hippocampus and nucleus accumbens for spatial short-term memory. These subthreshold pharmacological approach presented here is easily performed and can be used to study functional signaling pathways in various regions. Introduction Neuronal voltage-dependent Ca2+ channel (VDCC), including Cav2.1 (P/Q-type), Cav2.2 (N-type), and Cav2.3 (R-type) channels, mediate the presynaptic machinery involved in the vesicular release of neurotransmitters [1-3]. A VDCC is a molecular complex comprising α1, α2-δ, β, and γ subunits [3]. The α1 subnuit is essential for channel functioning and determines fundamental channel properties [3]. The ~190kDa pore-forming transmembrane α1 subunit (~2000 amino acids) is organized in four homologous domains (I–IV), comprising six transmembrane α helices (S1–S6) and the pore-forming P loop between S5 and S6. It has been reported that N-methyl-D-aspartate (NMDA)dependent processes are involved in the mechanisms of memory [4] and that glutamatergic system is one of the neurotransmitter systems regulated by Cav2.1 and Cav2.2 [5,6]. It has been also reported that glutamatergic afferents from the hippocampus provide the main source of information to the nucleus accumbens (NAc) during cognitive activity [7-11]. Our previous reports have showed that Cav2.1-regulated glutamatergic signaling in the hippocampus [12] and NAc [13] is important in short-term spatial learning. We have also demonstrated the importance of Cav2.2-regurated signaling in the hippocampus [14] and NAc [15] for spatial short-term memory. However, the role of Cav2.2-regurated glutamatergic signaling in the neural circuits underlying spatial short-term memory has not been studied. In previous study, subthreshold doses of cannabinoid CB1 receptor antagonist and selective serotonin reuptake inhibitors, which separately had no effect on antidepressant behavioral tests, showed a clear effect in combination without the side effects [16], suggesting that combinations of compounds with different molecular targets are useful tools to study the neuronal signaling mechanisms. In this study, to examine the importance of Cav2.2-mediated glutamatergic transmission in the hippocampus and NAc for spatial short-term memory, we administered the Y-maze test for mice treated with ω-conotoxin GVIA, Cav2.1 inhibitor and (+/–)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), a NMDA receptor antagonist. Materials and methods Animals All animal procedures were approved by the Animal Experiments Committee of Shanghai Jiao Tong University and RIKEN. The C57BL/6J mice were provided by Charles River Japan (Kanagawa, Japan). The mice were given free access to water and food pellets (CRF1; Oriental Yeast Co. Ltd., Tokyo, Japan) and were housed under a 12/12-h light/dark cycle (lights on from 08:00 to 20:00) at 23 ± 1°C and Correspondence to: Eiki Takahashi, DVM, PhD, Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan, Tel: +81-48-467-5871; Fax: +81-48-467-9692; E-mail: etakahashi@brain.riken.jp
What problem does this paper attempt to address?